Reveal Biosciences
CellCarta is a global Contract Research Organization (CRO) laboratory specializing in precision medicine by providing comprehensive biomarker testing solutions and services to the biopharmaceutical industry. Formed from the 2019 merger of Caprion Biosciences and HistoGeneX, and expanded through acquisitions like Clinical Logistics Inc., Mosaic Laboratories, and Biogazelle, CellCarta offers integrated immune monitoring, histopathology, proteomics, and genomics platforms. The company supports drug development from discovery through clinical phases with advanced technologies such as flow cytometry, mass cytometry, mass spectrometry, digital pathology, and genomic sequencing. Headquartered in Montreal, Canada, with over 700 employees across nine global facilities, CellCarta emphasizes scientific excellence, regulatory compliance (CAP, CLIA), and customized biomarker strategies to advance precision medicine and improve health outcomes worldwide.
Reveal Biosciences
CellCarta is a global Contract Research Organization (CRO) laboratory specializing in precision medicine by providing comprehensive biomarker testing solutions and services to the biopharmaceutical industry. Formed from the 2019 merger of Caprion Biosciences and HistoGeneX, and expanded through acquisitions like Clinical Logistics Inc., Mosaic Laboratories, and Biogazelle, CellCarta offers integrated immune monitoring, histopathology, proteomics, and genomics platforms. The company supports drug development from discovery through clinical phases with advanced technologies such as flow cytometry, mass cytometry, mass spectrometry, digital pathology, and genomic sequencing. Headquartered in Montreal, Canada, with over 700 employees across nine global facilities, CellCarta emphasizes scientific excellence, regulatory compliance (CAP, CLIA), and customized biomarker strategies to advance precision medicine and improve health outcomes worldwide.
TL;DR
Founded: August 2012 in San Diego, California
What they built: AI / computational pathology to analyze whole-slide microscope images for disease diagnosis and tissue biomarker assessment
Series A: Announced 2019-04-02; lead investor Intel Capital; amount undisclosed
Exit: Acquired in May 2021 (acquirer reported as Caprion / CellCarta)
Company Overview
Problem Domain
Improving disease diagnosis and tissue biomarker assessment from pathology slides using AI-powered image analysis.
Founded
2012
Industry
Pathology / Diagnostics
Tech Stack
Funding Track Record
Participation reported from GNI Japan (GNI Group) and PP Capital; amount undisclosed.
Investor Signal
“Series A led by Intel Capital with participation from GNI Japan (GNI Group) and PP Capital”